We are delighted to announce that the University of Cambridge Enterprise Fund IV and the Parkwalk Opportunities Fund have closed an investment in Predictimmune Limited, a spinout company from the University of Cambridge. Predictimmune is developing prognostic tests for immune-mediated conditions to aid their management and improve patient outcomes.

Their first offering, PredictImmune-CD, will be in the field of the inflammatory bowel disease.
Predictimmune has carried out considerable market research into the medical need for the tests and the health economic benefits that they will deliver. They have also performed clinical studies which have validated the test and patents have been filed in all major territories including the EU and US.

We believe that the management team are in a good position to utilise the strength of the academic team and their research to break new ground in the treatment of these immune-mediated conditions.